drugset / Trial / NCT00780169
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, the maximum tolerated dose and the recommended dose for phase II studies of a chemotherapy-combination of sorafenib, irinotecan, and 5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) as first-line treatment for metastatic colorectal cancer.
Timeline
- Start
- 2008-10
- Primary completion
- 2011-05
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 80 mg/m2 | — |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Background | Leucovorin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |